Adams Respiratory Therapeutics Inc
Adams Respiratory Therapeutics — Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conferen (February 2007)
21 slides from Adams Respiratory Therapeutics's conference presentation, Feb 8, 2007

Slide 1: Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference
Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference February 8, 2007

Slide 2: Safe Harbor
Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. (or "Adams") as of the date of this presentation and are naturally subject to uncertainty and cha

Slide 3: A Specialty Pharmaceutical Company
A Specialty Pharmaceutical Company Adams is focused on: Developing a range of solutions that treat respiratory disease Late-stage development and marketing of differentiated OTC and Rx pharmaceutical brands

Slide 4: Adams' Business Strategy
Adams' Business Strategy Build internal pipeline by extending guaifenesin platform to other OTC & Rx respiratory segments Access platform technologies to accelerate product development Four - pronged strategy Drive Mucinex(r) brand awareness & market share among professionals and consumers Build Rx

Slide 5: Strong Growth in Revenues
12- Months Ended 6- Months Ended Strong Growth in Revenues (in millions) 6/03 12/05 6/04 6/05 YoY Growth 82% CAGR '03-'06 158 % 12/06 6/06 $239.1 $110.3

Slide 6: Mucinex Brand a Category Leader
Mucinex(r) Brand a Category Leader Mucinex(r) Brand a Category Leader SE 20's # 3 # 13 DM 20's # 6 # 22 SE 40's # 7 All OTC SKUs All Items Top 500 UPC Dollar Ranking at Drug Outlets (2) Higher ranking SKUs: 6 cigarettes 4 beverages 2 OTC products Source: Information Resources, Inc. (IRI) Brand Ranki

Slide 7: Dollar Market Share for Children's Mucinex and Delsym Continues to Accelerate
Dollar Market Share for Children's Mucinex(r) and Delsym(r) Continues to Accelerate Source: IRI data for the pediatric and cough syrup segments of the c/c/a/s category for the periods ended 12/31/06. +6.3 pts VYA +4.8 pts VYA +1.2 pts VYA

Slide 8: Adams Gaining Category Strength
Source: IRI data for the c/c/a/s market for the 4 weeks ended 12/31/06. Adams Gaining Category Strength Mucinex(r) Mucinex(r) DM Mucinex(r) D Mucinex(r) Children's Liquids Mucinex(r) Children's Mini-Melts Delsym(r) Dollar Share of C/C/A/S Category by Major Product +5.2 points VYA 3.7 3.5 1.2 0.7 0.5

Slide 9: Four Catalysts for Growth
Four Catalysts for Growth OTC Portfolio Diversification and Expansion FDA Exclusivity Decision on DM and D New Rx NDA Erdosteine

Slide 10: Accelerated Development and Diversification
Fiscal 2006 Fiscal 2007 Accelerated Development and Diversification Fiscal 2008 Expect to double existing portfolio

Slide 11: Mucinex SE, DM and D launch history and market size
Consumer Advertising February 2006 Competing Product Removal? Competing Product Removal? FDA Exclusivity Decision Pending Consumer Advertising November 2004 Competing Products Removed December 2003 Launched July 2002 Approved July 2002 $125 MM Rx market $20 MM Rx market Consumer Advertising November

Slide 12: Adams Seeks FDA Approval for its First Rx - A New Cough Suppressant
Adams Seeks FDA Approval for its First Rx - A New Cough Suppressant NDA submitted Dec. 2006 600/1200 mg guaifenesin (GGE) combinations Approx. 24 MM cough Rx's/year(1) Two other GGE products in development (1) Source: IMS Health NPA reports - MAT 2/06; MAT 3/06.

Slide 13: Erdosteine
Erdosteine In-licensed mucoregulator compound with a unique profile Improvements in mucociliary clearance, mucus volume, flow characteristics and cough(1) Approved in more than 30 foreign markets; approx. 24 million patient exposures Phase IIb clinical program completed Dec. 2006 400 patients with c

Slide 14: Financials
Financials

Slide 15: 2007 Fiscal Second Quarter Net Sales by Major Product
2007 Fiscal Second Quarter Net Sales by Major Product $39,224 $30,646 $9,130 $18,475 Acquired 6/06 $12,571 Launched 8/06 ($ in thousands) Accelerating Growth Rate Total Net Sales = $110.6 MM +75% vs. Q2 FY06

Slide 16: Top-Line Diversification Continues
Top-Line Diversification Continues Top-Line Diversification Continues $16.3 MM or ~34% $31.0 MM or ~66% Net Sales growth = $47.3 million

Slide 17: Income Statement Overview
Income Statement Overview $110.6 $63.2 $239.1 $160.2 $61.3 Net Sales 75.9% 78.0% 79.4% 80.6% 80.5% Gross Margin % $19.4 17.6% $17.4 27.5% $76.2 32% $44.4 28% $19.7 32% Pretax Income % of Net Sales $12.5 $10.7 $46.4 $27.0 $35.8 Net Income 2006 2005 2006 2005 2004 Three months ended Dec. 31, Years end

Slide 18: Year-Over-Year Operating Expenses: SG&A
Year-Over-Year Operating Expenses: SG&A Year-Over-Year Operating Expenses: SG&A Fiscal 2006 SG&A Spend: $99 MM Fiscal 2007 Estimated SG&A Spend: $168 - $172 MM

Slide 19

Slide 20: Future Growth Drivers
Future Growth Drivers Base-brand Market Share Expansion Successful Children's Mucinex(r) Launch Delsym(r) Acquisition and Growth Portfolio Diversification and Expansion New Combo Products Exclusivity Decision on DM and D Erdosteine Acquisitions/In-licensing Vision: Become a $1 billion company over a

Slide 21: Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference
Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference February 8, 2007
Source: SEC EDGAR · 8-K filed Feb 8, 2007
More decks from Adams Respiratory Therapeutics Inc
Q1 FY2008 Earnings Presentation12 slides · Nov 8, 2007
Q3 FY2007 Earnings Presentation21 slides · May 10, 2007
Technical Presentation (April 2007)25 slides · Apr 4, 2007
Investor Presentation (April 2007)10 slides · Apr 4, 2007
Investor Presentation (April 2007)60 slides · Apr 4, 2007
Q2 FY2007 Earnings Presentation28 slides · Feb 7, 2007